Literature DB >> 28127639

Increased Mer and Axl receptor tyrosine kinase expression on glomeruli in lupus nephritis.

Shanshan Li1,2, Qianyu Guo3, Huaqun Zhu1, Zhanguo Li1, Yin Su4, Bao Dong5.   

Abstract

Mer and Axl receptor tyrosine kinases (MerTK and AxlTK) play important roles in the clearance of apoptotic cells and the inhibition of inflammatory responses. Previous studies demonstrated that they might participate in glomerular injury in mice model. This study aimed to elucidate the expression of MerTK and AxlTK on glomeruli and analyze their clinical significance in lupus nephritis (LN) patients. Twenty-nine LN and 10 primary nephrotic syndrome (NS) patients were recruited. The expression of MerTK and AxlTK on glomeruli was measured by immunohistochemistry. Correlations between the levels of MerTK and AxlTK and clinical data were investigated. Statistical differences in each group were calculated by one-way analysis of variance, t test, or Mann-Whitney U test. Correlations were evaluated with Pearson's or Spearman's correlation tests. Both MerTK and AxlTK were expressed mainly on mesangial cells. LN patients demonstrated more expression of MerTK and AxlTK than primary NS patients (1.19 ± 1.01 × 10-2 vs 0.21 ± 0.29 × 10-2, 7.25 ± 2.69 × 10-2 vs 3.10 ± 1.22 × 10-2, p < 0.01). In LN patients, MerTK expression correlated with AxlTK (r = 0.529, p < 0.01). LN patients with class IV expressed more MerTK and AxlTK (1.50 ± 1.03 × 10-2 and 7.56 ± 2.93 × 10-2). The expression of MerTK and AxlTK varied according to the deposition of immunoglobulin and complements on glomeruli. Both MerTK and AxlTK expressions were increased on glomeruli and varied according to pathological classifications. Thus, we assumed that both two subsets might participate in the pathogenesis of LN.

Entities:  

Keywords:  Axl receptor tyrosine kinase; Immune disorder; Lupus nephritis; Mer receptor tyrosine kinase; Pathology

Mesh:

Substances:

Year:  2017        PMID: 28127639     DOI: 10.1007/s10067-017-3550-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

Review 1.  TAM receptor signaling and autoimmune disease.

Authors:  Carla V Rothlin; Greg Lemke
Journal:  Curr Opin Immunol       Date:  2010-10-26       Impact factor: 7.486

2.  Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.

Authors:  Gaetano Zizzo; Brendan A Hilliard; Marc Monestier; Philip L Cohen
Journal:  J Immunol       Date:  2012-08-31       Impact factor: 5.422

Review 3.  Mechanisms of immune-deposit formation and the mediation of immune renal injury.

Authors:  Masaomi Nangaku; William G Couser
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

4.  Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice.

Authors:  Fei Ye; Lixia Han; Qingjun Lu; Wanwei Dong; Zhenwen Chen; Hui Shao; Henry J Kaplan; Qiutang Li; Qingxian Lu
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

5.  Rethinking the red wolf disease: does Protein S suppress systemic lupus erythematosus clinical activity?

Authors:  Gregg J Silverman
Journal:  Arthritis Res Ther       Date:  2010-10-27       Impact factor: 5.156

6.  Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.

Authors:  Carl Ekman; Andreas Jönsen; Gunnar Sturfelt; Anders A Bengtsson; Björn Dahlbäck
Journal:  Rheumatology (Oxford)       Date:  2011-01-28       Impact factor: 7.580

Review 7.  Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Clin Dev Immunol       Date:  2012-06-14

8.  Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.

Authors:  Philip L Cohen; Roberto Caricchio; Valsamma Abraham; Todd D Camenisch; J Charles Jennette; Robert A S Roubey; H Shelton Earp; Glenn Matsushima; Elizabeth A Reap
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

Review 9.  The complement cascade and renal disease.

Authors:  Katarzyna Kościelska-Kasprzak; Dorota Bartoszek; Marta Myszka; Marcelina Zabińska; Marian Klinger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-09-13       Impact factor: 4.291

10.  Diversification of TAM receptor tyrosine kinase function.

Authors:  Anna Zagórska; Paqui G Través; Erin D Lew; Ian Dransfield; Greg Lemke
Journal:  Nat Immunol       Date:  2014-09-07       Impact factor: 25.606

View more
  4 in total

1.  Mesangioproliferative Kidney Diseases and Platelet-Derived Growth Factor-Mediated AXL Phosphorylation.

Authors:  Qi Bian; Joshua C Anderson; Xian Wen Zhang; Zhi Qiang Huang; Kerstin Ebefors; Jenny Nyström; Stacy Hall; Lea Novak; Bruce A Julian; Christopher D Willey; Jan Novak
Journal:  Kidney Med       Date:  2021-07-30

2.  Elevated expression of TAM receptor tyrosine kinase in synovial fluid and synovial tissue of rheumatoid arthritis.

Authors:  Li Zheng; Liling Xu; Fanlei Hu; Jimeng Xue; Mingxin Bai; Ranran Yao; Huaqun Zhu; Hua Zhong; Yin Su
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

3.  A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus.

Authors:  Hadijat M Makinde; Deborah R Winter; Daniele Procissi; Elise V Mike; Ariel D Stock; Mary J Kando; Gaurav T Gadhvi; Steven Droho; Christina L Bloomfield; Salina T Dominguez; Maximilian G Mayr; Jeremy A Lavine; Chaim Putterman; Carla M Cuda
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561

4.  Growth Arrest-Specific Gene 6 Administration Ameliorates Sepsis-Induced Organ Damage in Mice and Reduces ROS Formation In Vitro.

Authors:  Livia Salmi; Francesco Gavelli; Filippo Patrucco; Mattia Bellan; Pier Paolo Sainaghi; Gian Carlo Avanzi; Luigi Mario Castello
Journal:  Cells       Date:  2021-03-09       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.